Mizuho raised the firm’s price target on Sage Therapeutics to $45 from $37 and keeps a Neutral rating on the shares following the Q4 sales beat.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SAGE: